| |
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now. 
|
|
Today’s Big NewsJan 9, 2025 |
|
The U.S. Department of Veterans Affairs (VA) is at the forefront of healthcare innovation, developing cutting-edge technologies to improve the lives of veterans . Now, your business can leverage these advancements. Download today to learn more! 
|
|
| By James Waldron Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has arrived on the scene with an eye-popping series A. |
|
|
|
By Kevin Dunleavy With an on-body delivery system (OBDS) to deliver its subcutaneous (SC) formulation of Sarclisa, Sanofi may be finding the edge it needs to compete with Johnson & Johnson's Darzalex in multiple myeloma. Sanofi has taken a major step in the development of its OBDS as a phase 3 trial has met its primary co-endpoints, showing non-inferiority to intravenous (IV) Sarclisa, the company said. |
By Conor Hale The venture firm Vensana Capital has raised its third medtech-focused fund in the past six years, with $425 million in new commitments to support growing medical device and data science startups. |
By Gabrielle Masson Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million. |
|
As the market for complex biologics continues to grow, effective capacity planning becomes more challenging. The entry of the 5,000L single-use bioreactor (SUB) is providing an important bridge between small-scale and large-scale production, offering more flexibility than ever before to respond to fluctuations in demand quickly and efficiently. Access this report to learn more. 
|
|
By Angus Liu When the BIOSECURE Act missed the chance of becoming law in 2024, the deceleration of the draft legislation invited the question of whether two biotechs living under the shadow of the bill—Legend Biotech and BeiGene—should grasp the opportunity and seek an exit in 2025. |
By Conor Hale The series C round was co-led by Arboretum Ventures and Solas BioVentures, and joined by backers at Orlando Health Ventures, Coloplast and Tonkawa. |
By Nick Paul Taylor Bayer’s hot flash drug candidate has hit the mark in a phase 3 breast cancer trial, potentially positioning the German drugmaker to get the jump on Astellas’ rival drug Veozah. |
By Fraiser Kansteiner Despite recent developments in the fight to corral high U.S. drug prices, the trend toward consistently rising costs—which has held true for years—is likely to persist for the foreseeable future. That's according to a recent TD Cowen report on the near-term drug pricing outlook in the U.S. |
By Darren Incorvaia It’s been a rough month for several clinical amyotrophic lateral sclerosis (ALS) candidates, but that’s not stopping Eli Lilly from pursuing new drugs of its own for the devastating neurological disease. The Big Pharma has inked a deal with British biotech Alchemab Therapeutics to develop new antibodies for ALS. |
By Fraiser Kansteiner Thanks to a new settlement with Catalyst, Teva is barred from marketing its Firdapse generic in the U.S. until Feb. 25, 2035, at the earliest. |
By Nick Paul Taylor Mendaera has found a leader with deep medical robotics experience to lead its commercialization push. Eric Davidson has taken up the chief commercial officer position at Mendaera, positioning him to apply experience gained at companies including Intuitive Surgical to the launch of a handheld robotic platform. |
By Fraiser Kansteiner Earlier this week, a study of Astellas’ autologous CAR-T asset ASP2802 in CD20-positive B-cell lymphomas was listed as terminated in the U.S.’ online clinical trial database. Astellas confirmed that it has stopped development on the candidate, which it attributed to "prioritization efforts." |
By Nick Paul Taylor Havas is forging deeper into the GLP-1 space with a series of YouTube videos about the drug class and its impact on the world. The ad agency is pitching the series as both a science-led initiative to separate fact from fiction and a project that will show the value of serialized episodic online content to brands. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees. |
|
|---|
|
|
|
With unique perspectives from key opinion leaders, this whitepaper examines the challenges associated with process development and manufacturing of cell and gene therapies. Download now to take your cell and gene therapy techniques to new heights. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
